A top Wall Street firm is recommending that investors buy Biogen because of a promising pipeline of drugs it is developing to treat Alzheimer’s disease.
Biogen shares rose 4 percent shortly after Thursday’s market open.
Morgan Stanley raised its rating for Biogen shares to overweight from equal-weight, citing the potential of the company’s upcoming therapies.
